Award
National Cancer Institute 9R42CA290612-03
Human T Cell Lymphotropic Virus Vaccine Development
Recipient
STINGINN, LLC
Award Amount
$999,969.00
Ceiling
$999,969.00
Awarded
August 15, 2024
Identifier
9R42CA290612-03
Award for development and testing of a vaccine for HTLV-1 by the National Cancer Institute. The project focuses on safety, immunogenicity, and efficacy evaluation of a VSV-based vaccine candidate, with a duration from 2022 to 2027.
Description
The project involves development and testing of a vaccine for HTLV-1. The project aims to evaluate safety, immunogenicity, and efficacy of the vaccine. The vaccine candidate is based on vesicular stomatitis virus (VSV) expressing HTLV-1 proteins. The project includes phases of safety assessment, immunogenicity testing, and potential Phase II trials.